• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AstraZeneca PLC - American Depositary Shares (NY:AZN)

    188.59 -6.56 (-3.36%)
    Streaming Delayed Price Updated: 12:08 PM EDT, Jul 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about AstraZeneca PLC - American Depositary Shares

    News headline image
    AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
    From AstraZeneca
    Via Business Wire
    BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies
    Via Investor Brand Network
    Topics Artificial Intelligence
    Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
    Via Investor Brand Network
    News headline image
    TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
    From AstraZeneca
    Via Business Wire
    News headline image
    IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
    From AstraZeneca
    Via Business Wire
    News headline image
    IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
    From AstraZeneca
    Via Business Wire
    News headline image
    AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
    From AstraZeneca
    Via Business Wire
    News headline image
    BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
    From AstraZeneca
    Via Business Wire
    News headline image
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
    From AstraZeneca
    Via Business Wire
    News headline image
    TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    AstraZeneca results: Q1 2026
    From AstraZeneca
    Via Business Wire
    News headline image
    BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
    From AstraZeneca
    Via Business Wire
    News headline image
    SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
    From AstraZeneca
    Via Business Wire
    News headline image
    Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
    From AstraZeneca
    Via Business Wire
    News headline image
    IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
    From AstraZeneca
    Via Business Wire
    News headline image
    AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
    From AstraZeneca
    Via Business Wire
    News headline image
    Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
    From AstraZeneca
    Via Business Wire
    News headline image
    AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
    From AstraZeneca
    Via Business Wire
    News headline image
    Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
    EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    AstraZeneca results: FY and Q4 2025
    From AstraZeneca
    Via Business Wire
    News headline image
    DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
    From AstraZeneca
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.